Skip to main
OABI
OABI logo

OmniAb Inc (OABI) Stock Forecast & Price Target

OmniAb Inc (OABI) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OmniAb Inc. demonstrates a robust outlook due to its significant progress in advancing both its proprietary portfolio and strategic partnerships, reflecting strong demand for its innovative therapeutic antibody discovery technologies. The anticipated 4Q24 financials suggest improved revenues of $12.3 million and a reduced net loss, indicating effective management of operational expenditures while expanding its discovery efforts. Furthermore, the continued expansion through new license agreements underlines OmniAb's commitment to building a diversified and technology-driven portfolio, which positions the company favorably for future growth and potential share price appreciation.

Bears say

OmniAb experienced a significant decline in revenue for 3Q24, reporting $4.2 million compared to $5.5 million in the same quarter of the previous year, alongside a widening net loss of $16.4 million. The downward trend in revenue is primarily attributed to lower license and service revenues, along with missed expectations of $10.9 million. Furthermore, projections for full-year revenues have decreased to $27.9 million from $34.2 million in 2023, highlighting challenges in securing adequate funding, achieving successful clinical trial outcomes, and commercial traction for its therapeutics.

OmniAb Inc (OABI) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OmniAb Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OmniAb Inc (OABI) Forecast

Analysts have given OmniAb Inc (OABI) a Strong Buy based on their latest research and market trends.

According to 9 analysts, OmniAb Inc (OABI) has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OmniAb Inc (OABI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.